Pieter J A Eichhorn
Overview
Explore the profile of Pieter J A Eichhorn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dewson G, Eichhorn P, Komander D
Nat Rev Cancer
. 2023 Nov;
23(12):842-862.
PMID: 37935888
Ubiquitination is an essential regulator of most, if not all, signalling pathways, and defects in cellular signalling are central to cancer initiation, progression and, eventually, metastasis. The attachment of ubiquitin...
2.
Teyra J, Singer A, Schmitges F, Jaynes P, Lui S, Polyak M, et al.
Structure
. 2019 Feb;
27(4):590-605.e5.
PMID: 30713027
The multi-domain deubiquitinase USP15 regulates diverse eukaryotic processes and has been implicated in numerous diseases. We developed ubiquitin variants (UbVs) that targeted either the catalytic domain or each of three...
3.
Kong L, Tan T, Ong W, Bi C, Huynh H, Lee S, et al.
Mol Oncol
. 2017 Apr;
11(8):965-980.
PMID: 28397399
There have been advances in personalized therapy directed by molecular profiles in lung adenocarcinoma, but not in lung squamous cell carcinoma (SCC). The lack of actionable driver oncogenes in SCC...
4.
Nguyen H, Andrejeva D, Gupta R, Choudhary C, Hong X, Eichhorn P, et al.
Cell Discov
. 2016 Jul;
2:16001.
PMID: 27462448
The Hippo pathway has been identified as a key barrier for tumorigenesis, acting through downregulation of YAP/TAZ activity. Elevated YAP/TAZ activity has been documented in many human cancers. Ubiquitylation has...
5.
Serra V, Eichhorn P, Garcia-Garcia C, Ibrahim Y, Prudkin L, Sanchez G, et al.
J Clin Invest
. 2013 May;
123(6):2551-63.
PMID: 23635776
The PI3K signaling pathway regulates diverse cellular processes, including proliferation, survival, and metabolism, and is aberrantly activated in human cancer. As such, numerous compounds targeting the PI3K pathway are currently...
6.
Eichhorn P, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, et al.
Nat Med
. 2012 Feb;
18(3):429-35.
PMID: 22344298
In advanced cancer, including glioblastoma, the transforming growth factor β (TGF-β) pathway acts as an oncogenic factor and is considered to be a therapeutic target. Using a functional RNAi screen,...
7.
Eichhorn P, Baselga J
J Clin Oncol
. 2010 Mar;
28(11):1809-10.
PMID: 20231675
No abstract available.
8.
Eichhorn P, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al.
Cancer Res
. 2008 Nov;
68(22):9221-30.
PMID: 19010894
Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is...
9.
Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M, et al.
Cancer Res
. 2008 Oct;
68(19):8022-30.
PMID: 18829560
Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homologue deleted from chromosome 10 or activating mutations of...
10.
Eichhorn P, Creyghton M, Bernards R
Biochim Biophys Acta
. 2008 Jul;
1795(1):1-15.
PMID: 18588945
The serine/threonine protein phosphatase (PP2A) is a trimeric holoenzyme that plays an integral role in the regulation of a number of major signaling pathways whose deregulation can contribute to cancer....